U.S. markets close in 3 hours 10 minutes

Biohaven Ltd. (BHVN)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
47.50+1.32 (+2.86%)
A partir del 12:49PM EST. Mercado abierto.

Biohaven Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo202

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Vladimir Coric M.D.Chairman & CEO1.85MN/D1971
Mr. Matthew ButenChief Financial Officer939.45kN/D1961
Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer646.89kN/D1962
Ms. Deb YoungDirector of Regulatory Affairs & OperationsN/DN/DN/D
Mr. George C. ClarkVP & Chief Accounting OfficerN/DN/D1984
Ms. Jennifer PorcelliVice President of Investor RelationsN/DN/DN/D
Mr. Warren Volles J.D.General Counsel & Chief Legal OfficerN/DN/DN/D
Mr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerN/DN/DN/D
Ms. Kimberly GentileSenior Vice President of Clinical OperationsN/DN/D1966
Mr. John TiltonChief Commercial Officer of Rare DiseasesN/DN/D1968
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Gestión corporativa

La calificación ISS Governance QuickScore de Biohaven Ltd. a partir del 1 de febrero de 2024 es 5. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 3; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.